Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Pruvanserin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A known ✓ | P28223 | 6/20 | 0.93 |
| ▸ | HTR2C | P28335 | 4/20 | 0.93 |
| ▸ | DRD4 | P21917 | 1/20 | 0.93 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.93 |
| ▸ | HTR1D | P28221 | 1/20 | 0.93 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.93 |
| ▸ | HTR7 | P34969 | 1/20 | 0.93 |
| ▸ | HTR2B | P41595 | 1/20 | 0.93 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.93 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.93 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.72 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.41 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pruvanserin SCHEMBL3914362 | 1.00 | HTR2A (0.93) | HTR2AHTR2CDRD4SLC6A2HTR1D | |
| Pruvanserin SCHEMBL29379046 | 0.96 | HTR2A (1.00) | HTR2AHTR2CDRD4SLC6A2HTR1D | |
| Pruvanserin SCHEMBL9104227 | 0.96 | HTR2A (1.00) | HTR2AHTR2CDRD4SLC6A2HTR1D | |
| Pruvanserin SCHEMBL678751 | 0.96 | HTR2A (1.00) | HTR2AHTR2CDRD4SLC6A2HTR1D | |
| Pruvanserin SCHEMBL29489913 | 0.95 | HTR2A (0.98) | HTR2AHTR2CDRD4SLC6A2HTR1D | |
| Pruvanserin SCHEMBL678953 | 0.95 | HTR2A (0.98) | HTR2AHTR2CDRD4SLC6A2HTR1D | |
| SCHEMBL6110393 | 0.88 | HTR2A (0.84) | HTR2AHTR2CDRD4SLC6A2HTR1D | |
| SCHEMBL5280317 | 0.88 | HTR2A (0.84) | HTR2AHTR2CDRD4SLC6A2HTR1D | |
| SCHEMBL6112038 | 0.87 | HTR2A (0.83) | HTR2AHTR2CDRD4SLC6A2HTR1D | |
| SCHEMBL5925660 | 0.84 | HTR2A (1.00) | HTR2AHTR2CDRD4SLC6A2HTR1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2016052-B1 | CRYSTALLINE (3-CYANO-1H-INDOL-7-YL)-[4-(4-FLUOROPHENETHYL)PIPERAZIN-1-YL]METHANONE PHOSPHATE | MERCK PATENT GMBH (DE) | 2012-06-06 | — | — | EP | claimed |
| US-8188087-B2 | Crystalline (3-cyano-1H-indol-7-yl)-[4-(4-fluorophenethyl) piperazin-1-yl]methanone phosphate | MERCK PATENT GMBH (DE) | 2012-05-29 | — | — | US | claimed |
| US-20090221606-A1 | CRYSTALLINE (3-CYANO-1H-INDOL-7-YL)-[4-(4-FLUOROPHENETHYL) PIPERAZIN-1-YLIMETHANONE PHOSPHATE | MERCK PATENT GESELLSCHAFT (DE) | 2009-09-03 | — | — | US | claimed |
| EP-2016052-A1 | CRYSTALLINE (3-CYANO-1H-INDOL-7-YL)-[4-(4-FLUOROPHENETHYL)PIPERAZIN-1-YL]METHANONE PHOSPHATE | ELI LILLY AND COMPANY (US) | 2009-01-21 | — | — | EP | claimed |
| WO-2007130814-A1 | CRYSTALLINE (3-CYANO-1H-INDOL-7-YL)-[4-(4-FLUOROPHENETHYL)PIPERAZIN-1-YL]METHANONE PHOSPHATE | MERCK PATENT GMBH (DE) | 2007-11-15 | — | — | WO | claimed |
| CN-101437793-B | Crystalline (3-cyano-1H-indol-7-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone phosphate | MERCK PATENT GMBH | 2012-08-22 | — | — | CN | disclosed |
| CN-101437793-B | Crystalline (3-cyano-1H-indol-7-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone phosphate | MERCK PATENT GMBH | 2012-08-22 | — | — | CN | disclosed |
| EP-2016052-B1 | CRYSTALLINE (3-CYANO-1H-INDOL-7-YL)-[4-(4-FLUOROPHENETHYL)PIPERAZIN-1-YL]METHANONE PHOSPHATE | MERCK PATENT GMBH (DE) | 2012-06-06 | — | — | EP | disclosed |
| EP-2016052-B1 | CRYSTALLINE (3-CYANO-1H-INDOL-7-YL)-[4-(4-FLUOROPHENETHYL)PIPERAZIN-1-YL]METHANONE PHOSPHATE | MERCK PATENT GMBH (DE) | 2012-06-06 | — | — | EP | disclosed |
| EP-2016052-B1 | CRYSTALLINE (3-CYANO-1H-INDOL-7-YL)-[4-(4-FLUOROPHENETHYL)PIPERAZIN-1-YL]METHANONE PHOSPHATE | MERCK PATENT GMBH (DE) | 2012-06-06 | — | — | EP | disclosed |
| US-8188087-B2 | Crystalline (3-cyano-1H-indol-7-yl)-[4-(4-fluorophenethyl) piperazin-1-yl]methanone phosphate | MERCK PATENT GMBH (DE) | 2012-05-29 | — | — | US | disclosed |
| US-8188087-B2 | Crystalline (3-cyano-1H-indol-7-yl)-[4-(4-fluorophenethyl) piperazin-1-yl]methanone phosphate | MERCK PATENT GMBH (DE) | 2012-05-29 | — | — | US | disclosed |
| CN-101437793-A | Crystalline (3-cyano-1H-indol-7-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone phosphate | MERCK PATENT GMBH (DE) | 2009-05-20 | — | — | CN | disclosed |
| CN-101437793-A | Crystalline (3-cyano-1H-indol-7-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone phosphate | MERCK PATENT GMBH (DE) | 2009-05-20 | — | — | CN | disclosed |
| EP-2016052-A1 | CRYSTALLINE (3-CYANO-1H-INDOL-7-YL)-[4-(4-FLUOROPHENETHYL)PIPERAZIN-1-YL]METHANONE PHOSPHATE | ELI LILLY AND COMPANY (US) | 2009-01-21 | — | — | EP | disclosed |
| EP-2016052-A1 | CRYSTALLINE (3-CYANO-1H-INDOL-7-YL)-[4-(4-FLUOROPHENETHYL)PIPERAZIN-1-YL]METHANONE PHOSPHATE | ELI LILLY AND COMPANY (US) | 2009-01-21 | — | — | EP | disclosed |
| EP-2016052-A1 | CRYSTALLINE (3-CYANO-1H-INDOL-7-YL)-[4-(4-FLUOROPHENETHYL)PIPERAZIN-1-YL]METHANONE PHOSPHATE | ELI LILLY AND COMPANY (US) | 2009-01-21 | — | — | EP | disclosed |
| WO-2007130814-A1 | CRYSTALLINE (3-CYANO-1H-INDOL-7-YL)-[4-(4-FLUOROPHENETHYL)PIPERAZIN-1-YL]METHANONE PHOSPHATE | MERCK PATENT GMBH (DE) | 2007-11-15 | — | — | WO | disclosed |
| WO-2007130814-A1 | CRYSTALLINE (3-CYANO-1H-INDOL-7-YL)-[4-(4-FLUOROPHENETHYL)PIPERAZIN-1-YL]METHANONE PHOSPHATE | MERCK PATENT GMBH (DE) | 2007-11-15 | — | — | WO | disclosed |
| WO-2007130814-A1 | CRYSTALLINE (3-CYANO-1H-INDOL-7-YL)-[4-(4-FLUOROPHENETHYL)PIPERAZIN-1-YL]METHANONE PHOSPHATE | MERCK PATENT GMBH (DE) | 2007-11-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221606-A1 | CRYSTALLINE (3-CYANO-1H-INDOL-7-YL)-[4-(4-FLUOROPHENETHYL) PIPERAZIN-1-YLIMETHANONE PHOSPHATE | PPIP5K2, IP6K3, IPMK | HTR2A 522/4885HTR2C 192/4885DRD4 2298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.